Clinical Trials
5-Year Survival Did Not Differ With Robotic Versus Laparoscopic Gastrectomy
Kitadani et alGastric Cancer

The trial enrolled 241 patients with clinical stage I–III resectable gastric cancer between April 1, 2018, and October 31, 2020, with 236 patients analyzed in the modified intention-to-treat cohort. While primary endpoint outcomes regarding postoperative intra-abdominal infectious complications were previously reported, this secondary analysis examined 5-year relapse-free survival, overall survival, and recurrence patterns.
In the modified intention-to-treat population, 5-year relapse-free survival was 75% in the robotic gastrectomy group compared with 69% in the laparoscopic gastrectomy group, and 5-year overall survival was 79% versus 71%, with neither comparison reaching statistical significance. The 5-year cumulative incidence of primary disease-specific death was comparable between groups at 11.6% for robotic gastrectomy versus 16.1% for laparoscopic gastrectomy, and patterns of disease recurrence did not differ.
Subgroup analyses identified specific cohorts with differing outcomes: robotic gastrectomy was associated with significantly better overall survival among male patients compared with laparoscopic gastrectomy (hazard ratio, 0.48; 95% CI, 0.25–0.95). In addition, among patients who underwent distal gastrectomy, robotic gastrectomy showed a significantly lower cumulative incidence of primary disease-specific death compared to the laparoscopic approach (hazard ratio, 0.24; 95% CI, 0.07–0.81). Trial registration: UMIN000031536.
Key Takeaways
- In the modified intention-to-treat population, 5-year relapse-free survival (75% vs 69%) and overall survival (79% vs 71%) did not differ significantly between robotic gastrectomy and laparoscopic gastrectomy.
- In subgroup analyses, robotic gastrectomy demonstrated significantly improved overall survival among male patients (HR 0.48; 95% CI, 0.25–0.95) and a significantly lower cumulative incidence of disease-specific death among patients undergoing distal gastrectomy (HR 0.24; 95% CI, 0.07–0.81).
Read the original sourceGastric Cancer
